Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

Elías, Isabel; Oyagüez, Itziar; Álvarez-Sala, Luis Antonio; García-Bragado, Fernando; Navarro, Andrés; González, Paloma; Andrés-Nogales, Fernando de; Soto, Javier.
Farm. hosp ; 40(3): 187-208, mayo-jun. 2016. fig, tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-152840

Documentos relacionados

  1. Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature.
  2. Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.
  3. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
  4. How I treat obese patients with oral anticoagulants.
  5. Anticoagulation Therapy in Children.
  6. Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.
  7. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
  8. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
  9. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
  10. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.